# A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

> **NCT07389499** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Grit Biotechnology** · enrollment: 30 (estimated)

## Conditions studied

- IgA Nephropathy (IgAN)
- Membranous Nephropathy
- ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)
- Refractory Podocytopathy
- Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits

## Interventions

- **BIOLOGICAL:** CD19-targeted iNKT Cell Injection

## Key facts

- **NCT ID:** NCT07389499
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07389499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07389499, "A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07389499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*